Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$14.47 USD
+0.09 (0.63%)
Updated Oct 6, 2025 04:00 PM ET
After-Market: $14.41 -0.06 (-0.41%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADPT 14.47 +0.09(0.63%)
Will ADPT be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
Other News for ADPT
Adaptive Biotechnologies: Current Moat Is Strong, But Value Rides On Long-Term Innovation (Rating Upgrade)
ADPT forms Upper Bollinger Band Walk on October 3
Is ADPT poised for gains? Slingshot Bullish shows up after slipping 0.76%
Is ADPT set to rally? New 52 Week High shows up after declining 2.67%
Is ADPT positioned for a breakout? New 52 Week Closing High shows up after surging 11.14%